Ropes & Gray represented ANI Pharmaceuticals, Inc. in its recommended public offer to acquire Egetis Therapeutics, a commercial-stage rare disease pharmaceutical company, for approximately $560 million. The offer was announced on November 5.
Egetis' lead product, EMCITATE, is the first and only approved treatment in the U.S. and Europe for peripheral thyrotoxicosis in patients with MCT8 deficiency, a rare genetic disorder.
ANI Pharmaceuticals is a diversified biopharmaceutical company focused on delivering novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology.
The Ropes & Gray team was led by capital markets partner Zach Blume and included litigation and enforcement partner Lisa Kaltenbrunner.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.